Douglas J Swirsky insider trades
Open-market stock purchases and sales by Douglas J Swirsky, Director at Cellectar Biosciences, Inc, from SEC Form 4 filings since Jan 20, 2010.
Track record: 100% of 2 scored buys are up 5% or more since purchase, averaging +12%.
Companies traded
- CLRB Cellectar Biosciences, Inc: 1 buy, last Jul 7, 2026
- MXCT Maxcyte, Inc: 1 buy, 2 sales, last Mar 17, 2026
- NRBO NeuroBo Pharmaceuticals, Inc: other filings, last Sep 1, 2020
- FCSC Fibrocell Science, Inc: other filings, last Dec 13, 2019
- RNN Rexahn Pharmaceuticals, Inc: other filings, last Nov 14, 2018
- PTX Pernix Therapeutics Holdings, Inc: other filings, last May 22, 2018
- GNVC Genvec Inc: 15 buys, last Jun 16, 2017
- PYMX.OB Polymedix, Inc: other filings, last Mar 26, 2012